The announcement comes after Austria stopped using a batch of AstraZeneca shots while investigating a death from coagulation disorders and an illness from a pulmonary embolism.

Still, the use medicine regulator said the vaccine's benefits outweighed the risks and could continue to be administered.

Denmark suspended the AstraZeneca shots for two weeks after a 60 year old woman who was given a shot from the same batch used in Austria, formed a blood clot and died, Denmark said.

The suspension was also prompted by reports quote of possible serious side effects from other European countries.

Some health experts said there was little evidence to suggest the AstraZeneca vaccine should not be administered.

One expert told Reuters.

It's extremely difficult to distinguish a causal effect from a coincidence.

AstraZeneca told Reuters in a written statement that the safety of its vaccine had been extensively studied in human trials, and peer reviewed data confirmed it was generally well tolerated.

The drug maker said this week there had been quote no confirmed serious adverse events associated with the vaccine.

It also said it was in contact with Austrian authorities about the death and would fully support their investigation.